ÂÜÀòÂÒÂ×

Dr. Peter L. Toogood joined Lycera in 2007 as VP of Chemistry and Chemical Biology. He previously held the titles of senior research associate, associate director, and research fellow at Parke-Davis/Pfizer in Ann Arbor, Michigan. His drug discovery experience encompasses the fields of immunology/inflammation, infectious diseases, and cancer. Dr. Toogood was a co-inventor of the cyclin-dependent kinase-4 inhibitor Palbociclib. Before joining Parke-Davis, Dr. Toogood served on the chemistry faculty of the University of Michigan in Ann Arbor, where he established an NIH and NSF-funded research program in natural products total synthesis and chemical biology.

Dr. Toogood received his Ph.D. from Imperial College, London, working with Professor Steven V. Ley, and was a NATO postdoctoral fellow in the laboratory of Professor Jeremy R. Knowles at Harvard University.

He is an author of more than 40 peer-reviewed publications and an inventor on 20 issued patents and pending patent applications. Dr. Toogood is an adjunct professor at the University of Michigan, College of Pharmacy.